Unlike bisphosphonates which are metabolized by the kidneys, Angarve® has an advantage in renal safety because it is metabolized by the reticuloendothelial system and not eliminated by the kidneys.
Unlike bisphosphonates, which are metabolized by the kidneys, ® has an advantage in kidney safety because it is metabolized through the mesh endothyl system and not removed through the kidneys
Unlike bisphosphonates that are metabolized through the kidney, agavix has an advantage in renal safety because it is metabolized through the reticuloendothelial system rather than eliminated by the kidney